Evidence map›Paper›PMID 19690041›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2009

A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression.

Gang Ren, Rong Zhang, Zhe Liu, Jack M Webster, Zheng Miao, Sanjiv S Gambhir, Faisal A Syud, Zhen Cheng

Open access · bronzeAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 65 citations in OpenAlex.

  1. Review
  2. Review
  3. Ovarian Cancer Targeted Theranostics.Frontiers in oncology · 2019
    Review
  4. Article
  5. Article
  6. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. 177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2012
    Article
  14. Article
  15. Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012
    Article
  16. Review
  17. A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor.European journal of nuclear medicine and molecular imaging · 2011
    Article
  18. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.European journal of nuclear medicine and molecular imaging · 2011
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gang RenMolecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University, Stanford, California, USA.
Rong Zhang
Zhe Liu
Jack M Webster
Zheng Miao
Sanjiv S Gambhir
Faisal A Syud
Zhen Cheng
Stanford University · USGeneral Electric (United States) · US

Funding

Spatiotemporal Analysis of Neoplasia in Animal ModelsR24CA092862 · NCI · STANFORD UNIVERSITY · PI CONTAG, CHRISTOPHER H · 2001 to 2006
$4.4M
NCI NIH HHS R24 CA092862NCI NIH HHS R24 CA93862
6 · The paper itself

Abstract

unlabelledAffibody molecules are a class of scaffold proteins being developed into a generalizable approach to targeting tumors. Many 3-helix-based Affibody proteins have shown excellent in vivo properties for tumor imaging and therapy. By truncating one alpha-helix that is not responsible for receptor recognition in the Affibody and maturating the protein affinity through synthetic strategies, we have successfully identified in our previous research several small 2-helix proteins with excellent binding affinities to human epidermal growth factor receptor type 2 (HER2). With preferential properties such as faster blood clearance and tumor accumulation, lower immunogenic potential, and facile and economically viable synthetic schemes, we hypothesized that these 2-helix protein binders could become excellent molecular imaging probes for monitoring HER2 expression and modulation.

methodsIn this study, a 2-helix small protein, MUT-DS, was chemically modified with a metal chelator, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). DOTA-MUT-DS was then site-specifically radiolabeled with an important PET radionuclide, (68)Ga. The resulting radiolabeled anti-HER2 2-helix molecule was further evaluated as a potential molecular probe for small-animal PET HER2 imaging in a SKOV3 tumor mouse model.

resultsThe 2-helix DOTA-MUT-DS showed high HER2-binding affinity (dissociation constant, 4.76 nM). The radiolabeled probe displayed high stability in mouse serum and specificity toward HER2 in cell cultures. Biodistribution and small-animal PET studies further showed that (68)Ga-DOTA-MUT-DS had rapid and high SKOV3 tumor accumulation and quick clearance from normal organs. The specificity of (68)Ga-DOTA-MUT-DS for SKOV3 tumors was confirmed by monitoring modulation of HER2 protein on treatment of tumor mice with heat shock protein 90 inhibitor 17-N,N-dimethyl ethylene diamine-geldanamycin in vivo.

conclusionThis proof-of-concept research clearly demonstrated that synthetic 2-helix (68)Ga-DOTA-MUT-DS is a promising PET probe for imaging HER2 expression in vivo. The Affibody-derived small 2-helix protein scaffold has great potential for developing targeting agents for a variety of tumor-associated biomarkers.

Indexed as

AnimalsCarrier ProteinsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleGallium RadioisotopesGene Expression ProfilingHumansMetabolic Clearance RateMiceMice, NudeOrgan SpecificityOvarian NeoplasmsPositron-Emission TomographyRadiopharmaceuticalsTissue DistributionCarrier ProteinsErb-b2 Receptor Tyrosine KinasesGallium RadioisotopesRadiopharmaceuticals

Identifiers

PMID19690041
PMCPMC4216181
OpenAlexW2105268352

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.